Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$217.04 USD

217.04
1,669,476

+3.68 (1.72%)

Updated Jun 26, 2026 04:00 PM ET

After-Market: $216.83 -0.21 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.94%
2Buy18.19%
3Hold10.25%
4Sell5.78%
5Strong Sell3.18%
S&P50011.60%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (55 out of 245)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

Why DaVita HealthCare (DVA) Dipped More Than Broader Market Today

by Zacks Equity Research

DaVita HealthCare (DVA) reached $111.01 at the closing of the latest trading day, reflecting a -3.23% change compared to its last close.

Zacks Equity Research

DaVita HealthCare (DVA) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $116.51, denoting a +1.14% move from the preceding trading day.

Zacks Equity Research

Zacks Industry Outlook Highlights Encompass Health, DaVita, Option Care Health and The Pennant

by Zacks Equity Research

Encompass Health is in focus as outpatient and home healthcare shifts toward AI, telehealth and cost-efficient care models.

Zacks Equity Research

4 Outpatient Home Health Stocks in Focus as Market Dynamics Change

by Zacks Equity Research

An aging population and rising AI adoption position the Zacks Medical - Outpatient and Home Healthcare industry for solid growth. EHC, DVA, OPCH and PNTG stand to benefit.

Zacks Equity Research

Here's Why You Should Hold DaVita Stock in Your Portfolio for Now

by Zacks Equity Research

DVA stock gets support from a patient-centric model, Q3 revenue growth and overseas expansion, even as reliance on commercial payers remains a risk.

Zacks Equity Research

Why Is DaVita HealthCare (DVA) Up 1.1% Since Last Earnings Report?

by Zacks Equity Research

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

DaVita Stock Down Post Q3 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.

Zacks Equity Research

DaVita HealthCare (DVA) Q3 Earnings Lag Estimates

by Zacks Equity Research

DaVita HealthCare (DVA) delivered earnings and revenue surprises of -23.71% and +0.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Can Technology and Cost Discipline Lift DaVita's Q3 Earnings?

by Zacks Equity Research

DVA's third-quarter 2025 performance is likely to benefit from technology upgrades and cost control while battling high missed treatments and low volume growth.

Zacks Equity Research

DaVita HealthCare (DVA) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

DaVita HealthCare (DVA) concluded the recent trading session at $128.05, signifying a +1.72% move from its prior day's close.